Verano Holdings just posted its Q2 2026 results and the headline is simple. Revenue reached about US$217.9 million while the business still reported a loss, with basic earnings per share at roughly US$0.18 in the red.
Investors came into this report with a stock that has drifted lower, down about 9% over the past three months to CA$6.93, and a reputation built on a long thesis of eventual profitability and a relatively low price-to-sales ratio. Today's report narrows that earnings hole and keeps the cash generation story in play, even as the trailing twelve-month figures still show deep red ink.
Love Verano Holdings for the revenue base and cash story, but concerned about the continuing losses. Compare it with profitable peers with solid finances in our list of solid balance sheet and fundamentals stocks (6 results)
Earnings for Verano Holdings tell one story, but investors who care about what the business can actually fund and sustain tend to focus on cash being generated and reinvested over time instead of accounting losses in a single quarter.
When you line up Verano Holdings' cash flows against its current share price, the numbers in the model suggest the stock could be a mild 11% undervalued.
The bullish view depends on Verano Holdings turning its footprint and cost work into reliable cash that outlives promotions and heavy CapEx.
"The main thing that has to go right is that Verano converts its strong medical footprint, product rollouts and cost efficiency program into sustained cash generation, while managing price pressure and higher planned 2026 CapEx."
Q3 results move that thesis from theory to evidence. Retail revenue grew while wholesale pulled back as management walked away from low margin deals. Operating cash flow of US$49 million, the highest in roughly four years, together with US$102 million of cash and a sharply smaller quarterly net loss all support the claim of improving, repeatable cash generation even as annual CapEx guidance rises.
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all.
The harsher view argues that margin pressure and discounting will keep Verano Holdings stuck in low quality profitability.
"While management points to operational efficiency efforts and prior SG&A reductions as a way to counter discounting, the Q2 2026 gross profit of $100 million at a 46% margin and adjusted EBITDA of $51 million at a 24% margin both declined versus the prior year. This indicates that promotional activity and price compression may continue to offset future cost programs and weigh on margin resilience."
Q3 shows some pushback against that worry. Gross profit held at US$100 million with a 47% margin and adjusted EBITDA stayed at 24%. Yet net income remained a US$4 million loss, so the profitability gap is not closed and the stock price, down roughly 9% over 90 days, suggests investors are still treating the margin story as unproven.
Verano Holdings reported results that paired a tighter cash position with ongoing losses. The real opportunity is assessing stocks that could be undervalued before the market potentially narrows any disconnect.
Three companies from the same screener. Open every one of the 3 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com